Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
Tracking Information | |
---|---|
First Received Date ICMJE | April 11, 2005 |
Last Updated Date | July 10, 2009 |
Start Date ICMJE | May 2005 |
Primary Completion Date | |
Current Primary Outcome Measures ICMJE |
- Evaluate the safety of a single IV administration of Ad.hIFN-β. |
Original Primary Outcome Measures ICMJE | Same as current |
Change History | Complete list of historical versions of study NCT00107861 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE |
|
Original Secondary Outcome Measures ICMJE |
|
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases |
Official Title ICMJE | A Phase I/II Study of Interferon-Beta Gene Transfer (Ad.hIFN-β) in the Treatment of Refractory Colorectal Carcinoma With Liver Metastases |
Brief Summary | This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are:
|
Detailed Description | This trial is a clinical research study of Ad.hIFN-β, an investigational, replication-defective, recombinant adenovirus containing the human interferon beta gene, for people that have refractory colorectal carcinoma with liver metastases. Scientists have been exploring a variety of approaches to develop medications to treat patients with refractory colorectal carcinoma with liver metastases; a disease for which current treatment provides only limited relief, so there is a need for new medications. |
Study Type ICMJE | Interventional |
Study Phase | Phase 1 Phase 2 |
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Condition ICMJE |
|
Intervention ICMJE | Drug: Ad.hIFN-β (BG00001, IDEC-201) |
Study Arm (s) | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Completed |
Enrollment ICMJE | 44 |
Completion Date | September 2006 |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | United States |
Administrative Information | |
NCT Number ICMJE | NCT00107861 |
Other Study ID Numbers ICMJE | 201-20 |
Has Data Monitoring Committee | |
Responsible Party | Study MD |
Study Sponsor ICMJE | Biogen Idec |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | Biogen Idec |
Verification Date | July 2009 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |